EZZ Life Sciences posts strong financial performance for December quarter
Genomic life science company EZZ Life Science (ASX: EZZ) posted a strong financial performance for the three months to December 2022, with $8.6 million in customer cash receipts representing an increase of 43% on the previous quarter and 132% on the same period last year.